Protagenic Therapeutics, Inc. - Common Stock (PTIX)
6.8800
-4.2200 (-38.02%)
NASDAQ · Last Trade: May 20th, 11:07 PM EDT
Detailed Quote
Previous Close
11.10
Open
8.700
Bid
6.100
Ask
6.230
Day's Range
6.400 - 9.860
52 Week Range
0.1790 - 14.28
Volume
4,007,970
Market Cap
4.05M
PE Ratio (TTM)
-2.117
EPS (TTM)
-3.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
4,972,149
Chart
About Protagenic Therapeutics, Inc. - Common Stock (PTIX)
Protagenic Therapeutics Inc is a biotechnology company focused on the development of innovative therapies for neurological and psychiatric disorders. The company leverages its proprietary technologies to identify and develop peptides that target specific neuronal pathways, with the aim of addressing unmet medical needs in conditions such as depression and anxiety. Through its research and development efforts, Protagenic Therapeutics seeks to create effective treatment options that can enhance the quality of life for patients suffering from these complex disorders. Read More
Curious to know what's happening on the US markets one hour before the close of the markets on Tuesday? Join us as we explore the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
Protagenic Therapeutics shares soared 240% Monday on its all-stock merger with Phytanix Bio. New Phytanix targets CNS disorders with an expanded diverse pipeline and experienced team.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Protagenic Therapeutics, Inc. (NASDAQ: PTIX) and Phytanix Bio Inc. is fair to Protagenic shareholders. Upon completion of the proposed transaction, Protagenic shareholders are expected to own approximately 35% of the combined company.
BALA CYNWYD, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused on stress-related and CNS disorders, five preclinical assets and one clinical-stage asset.
